From Influenza to COVID-19: Lipid Nanoparticle MRNA Vaccines at the Frontiers of Infectious Diseases

Overview

Journal Acta Biomater

Publisher Elsevier

Specialty Biomedical Engineering

Date 2021 Jun 21

PMID 34153512

Citations 86

Authors

Emily H Pilkington

Estelle J A Suys

Natalie L Trevaskis

Adam K Wheatley

Danijela Zukancic

Azizah Algarni

Hareth Al-Wassiti

Thomas P Davis

Colin W Pouton

Stephen J Kent

Nghia P Truong

Affiliations

Soon will be listed here.

Abstract

Vaccination represents the best line of defense against infectious diseases and is crucial in curtailing pandemic spread of emerging pathogens to which a population has limited immunity. In recent years, mRNA vaccines have been proposed as the new frontier in vaccination, owing to their facile and rapid development while providing a safer alternative to traditional vaccine technologies such as live or attenuated viruses. Recent breakthroughs in mRNA vaccination have been through formulation with lipid nanoparticles (LNPs), which provide both protection and enhanced delivery of mRNA vaccines in vivo. In this review, current paradigms and state-of-the-art in mRNA-LNP vaccine development are explored through first highlighting advantages posed by mRNA vaccines, establishing LNPs as a biocompatible delivery system, and finally exploring the use of mRNA-LNP vaccines in vivo against infectious disease towards translation to the clinic. Furthermore, we highlight the progress of mRNA-LNP vaccine candidates against COVID-19 currently in clinical trials, with the current status and approval timelines, before discussing their future outlook and challenges that need to be overcome towards establishing mRNA-LNPs as next-generation vaccines. STATEMENT OF SIGNIFICANCE: With the recent success of mRNA vaccines developed by Moderna and BioNTech/Pfizer against COVID-19, mRNA technology and lipid nanoparticles (LNP) have never received more attention. This manuscript timely reviews the most advanced mRNA-LNP vaccines that have just been approved for emergency use and are in clinical trials, with a focus on the remarkable development of several COVID-19 vaccines, faster than any other vaccine in history. We aim to give a comprehensive introduction of mRNA and LNP technology to the field of biomaterials science and increase accessibility to readers with a new interest in mRNA-LNP vaccines. We also highlight current limitations and future outlook of the mRNA vaccine technology that need further efforts of biomaterials scientists to address.

Citing Articles

Targeted delivery of TGF-β mRNA to murine lung parenchyma using one-component ionizable amphiphilic Janus Dendrimers.

Meshanni J, Stevenson E, Zhang D, Sun R, Ona N, Reagan E Nat Commun. 2025; 16(1):1806.

PMID: 39984450 PMC: 11845678. DOI: 10.1038/s41467-025-56448-y.

mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells.

Chen Z, Ren A, Li Y, Shu J, Wu J, Huang H Br J Haematol. 2025; 206(2):628-643.

PMID: 39761676 PMC: 11829146. DOI: 10.1111/bjh.19988.

Emerging Cationic Nanovaccines.

Carmona-Ribeiro A, Perez-Betancourt Y Pharmaceutics. 2024; 16(11).

PMID: 39598488 PMC: 11597065. DOI: 10.3390/pharmaceutics16111362.

Advances in mRNA LNP-Based Cancer Vaccines: Mechanisms, Formulation Aspects, Challenges, and Future Directions.

Ramadan E, Ahmed A, Naguib Y J Pers Med. 2024; 14(11).

PMID: 39590584 PMC: 11595619. DOI: 10.3390/jpm14111092.

Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach.

Haghighi E, Abolmaali S, Dehshahri A, Mousavi Shaegh S, Azarpira N, Tamaddon A J Nanobiotechnology. 2024; 22(1):710.

PMID: 39543630 PMC: 11566655. DOI: 10.1186/s12951-024-02972-w.

References

Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Narayanannair Jayaprakash K . Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010; 18(7):1357-64. PMC: 2911264. DOI: 10.1038/mt.2010.85. View

Dingler A, Blum R, Niehus H, Muller R, Gohla S . Solid lipid nanoparticles (SLN/Lipopearls)--a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J Microencapsul. 1999; 16(6):751-67. DOI: 10.1080/026520499288690. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

Levchenko T, Rammohan R, Lukyanov A, Whiteman K, Torchilin V . Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm. 2002; 240(1-2):95-102. DOI: 10.1016/s0378-5173(02)00129-1. View

Liu M . A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. Vaccines (Basel). 2019; 7(2). PMC: 6631684. DOI: 10.3390/vaccines7020037. View

Kariko K, Muramatsu H, Keller J, Weissman D . Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther. 2012; 20(5):948-53. PMC: 3345990. DOI: 10.1038/mt.2012.7. View

Pollard A . Childhood immunisation: what is the future?. Arch Dis Child. 2007; 92(5):426-33. PMC: 2083746. DOI: 10.1136/adc.2006.095760. View

Sahin U, Tureci O . Personalized vaccines for cancer immunotherapy. Science. 2018; 359(6382):1355-1360. DOI: 10.1126/science.aar7112. View

10.

Maruggi G, Zhang C, Li J, Ulmer J, Yu D . mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther. 2019; 27(4):757-772. PMC: 6453507. DOI: 10.1016/j.ymthe.2019.01.020. View

11.

Swartz M . The physiology of the lymphatic system. Adv Drug Deliv Rev. 2001; 50(1-2):3-20. DOI: 10.1016/s0169-409x(01)00150-8. View

12.

Kim E, Erdos G, Huang S, Kenniston T, Balmert S, Donahue Carey C . Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine. 2020; 55:102743. PMC: 7128973. DOI: 10.1016/j.ebiom.2020.102743. View

13.

Garg N, Tandel N, Jadon R, Tyagi R, Katare O . Lipid-polymer hybrid nanocarrier-mediated cancer therapeutics: current status and future directions. Drug Discov Today. 2018; 23(9):1610-1621. DOI: 10.1016/j.drudis.2018.05.033. View

14.

Wykes M, Pombo A, Jenkins C, MacPherson G . Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J Immunol. 1998; 161(3):1313-9. View

15.

Ercole F, Whittaker M, Quinn J, Davis T . Cholesterol Modified Self-Assemblies and Their Application to Nanomedicine. Biomacromolecules. 2015; 16(7):1886-914. DOI: 10.1021/acs.biomac.5b00550. View

16.

Geall A, Verma A, Otten G, Shaw C, Hekele A, Banerjee K . Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012; 109(36):14604-9. PMC: 3437863. DOI: 10.1073/pnas.1209367109. View

17.

Zuckerman J . The importance of injecting vaccines into muscle. Different patients need different needle sizes. BMJ. 2000; 321(7271):1237-8. PMC: 1118997. DOI: 10.1136/bmj.321.7271.1237. View

18.

Bloom K, van den Berg F, Arbuthnot P . Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2020; 28(3-4):117-129. PMC: 7580817. DOI: 10.1038/s41434-020-00204-y. View

19.

Cheng Q, Wei T, Jia Y, Farbiak L, Zhou K, Zhang S . Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I. Adv Mater. 2018; 30(52):e1805308. DOI: 10.1002/adma.201805308. View

20.

Imam Z, Kenyon L, Ashby G, Nagib F, Mendicino M, Zhao C . Phase-Separated Liposomes Enhance the Efficiency of Macromolecular Delivery to the Cellular Cytoplasm. Cell Mol Bioeng. 2017; 10(5):387-403. PMC: 5665383. DOI: 10.1007/s12195-017-0489-4. View